Desun Hospital & Heart Institute

St. Joseph's Hospital brings new treatment for AFib to Central Florida

Retrieved on: 
Monday, October 2, 2023
Heart, St. Joseph's Hospital, Heart failure, Intervention, Femoral vein, Atrial fibrillation, Stroke, Desun Hospital & Heart Institute, Cryotherapy, Dignity Health St. Joseph's Hospital and Medical Center, Cryoablation, Research, Hospital, MD, Patient, Physician, BayCare Ballpark, Arrhythmia, FDA, Medical imaging, Nursing, Central Florida, Ventricular fibrillation, Tampa Bay

TAMPA, Fla., Oct. 2, 2023 /PRNewswire/ -- A new cryoablation procedure designed to improve treatment of paroxysmal atrial fibrillation (AFib) is being offered by St. Joseph's Hospital Heart and Vascular Institute in Tampa.

Key Points: 
  • Kevin Makati, MD, and the St. Joseph's Hospital cardiovascular team perform a new cardiac ablation technique in Tampa.
  • The hospital, part of BayCare Health System, participated in the research trials of the equipment used.
  • Now, St. Joseph's is the first hospital in Central Florida and the third in the state to perform the ablation procedure after FDA-approval in September of a specialized cardiac cryoablation catheter for the treatment of AFib.
  • "This is yet another example of how the St. Joseph's Hospital Heart and Vascular Institute leads from the front," said Phil Minden, St. Joseph's Hospital president.

Recora and Tampa General Hospital Heart & Vascular Institute Partner to Offer New Cardiac Recovery Program to Thousands

Retrieved on: 
Thursday, September 8, 2022
Partnership, Patient, Degenerative disease, Technology, Division, Program, Tampa General Hospital, CDC, Forbes, News, GE Healthcare, Rehabilitation, Heart failure, Home, Standard of care, U.S. News & World Report Best Hospitals Rankings, Tower, Curriculum, Hospital, Cardiac rehabilitation, Innovation, Center, State, Fast Track, GLOBE, Neuroscience, Health, Medicare, Hypertension, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Desun Hospital & Heart Institute, Korea Disease Control and Prevention Agency, TGH, Adult, Round Top hospitals, Trauma, Marketing, Woman, Growth, Intensive care unit, Medicine

NEW YORK & TAMPA, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Recora today announced that it is partnering with the Tampa General Hospital Heart & Vascular Institute for its Cardiac Recovery Program.

Key Points: 
  • NEW YORK & TAMPA, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Recora today announced that it is partnering with the Tampa General Hospital Heart & Vascular Institute for its Cardiac Recovery Program.
  • This program will be the first of its kind in Florida's Tampa Bay region, expanding Tampa General Hospital's (TGH) outpatient cardiac rehabilitation program to more eligible patients in the academic medical center's 23-county service area.
  • "Cardiac rehabilitation with supervised, escalating doses of exerciseis crucial for complete recovery from a major cardiovascular surgery or procedure.
  • Guilherme Oliveira, professor and chief, Division of Cardiovascular Sciences, USF Health Morsani College of Medicine, and executive director,Tampa GeneralHeart & Vascular Institute.

Joe DiMaggio Children's Hospital (Hollywood, FL) Expands Cardiac Program

Retrieved on: 
Tuesday, June 21, 2022
Catheter, College, Rady Children's Hospital, Memorial Hermann Health System, Forbes, Baylor University Medical Center, Environment, Technology, Cardiology, News, Echocardiography, Electrophysiology, Hospital, Cleveland Clinic, Physician, U.S. News & World Report, YouTube, Desun Hospital & Heart Institute, Baylor University, University, College of Medicine, Detroit Medical Center, Heart transplantation, MRI, Twitter, Adult, Patient, Nemours Children's Hospital, Instagram, University of California, San Diego, Congenital heart defect, Stent, Dentistry, Medicine, Facebook

HOLLYWOOD, Fla., June 21, 2022 /PRNewswire-PRWeb/ -- Dr. Thomas Forbes, an interventional cardiologist, has joined Joe DiMaggio Children's Hospital as its chief of pediatric cardiac services. Forbes, previously at Detroit Medical Center in Michigan, is leading an expanding roster of cardiac specialists as the Hollywood-based children's facility significantly increases its size and capabilities while it adds four floors to the existing hospital building.

Key Points: 
  • HOLLYWOOD, Fla., June 21, 2022 /PRNewswire-PRWeb/ -- Dr. Thomas Forbes, an interventional cardiologist, has joined Joe DiMaggio Children's Hospital as its chief of pediatric cardiac services.
  • They will soon treat patients on a floor dedicated exclusively to cardiology when the expanded Joe DiMaggio Children's Hospital opens later this year.
  • Joe DiMaggio Children's Hospital has been included among the nation's top 50 for cardiology and heart surgery in the 2021-22 ranking of best children's hospitals by U.S. News & World Report.
  • Joe DiMaggio Children's Hospital is one of the nation's leading pediatric hospitals, offering a comprehensive scope of healthcare services and programs in a caring, compassionate setting designed specifically for children.

PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, November 10, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, MPH, Desun Hospital & Heart Institute, Director, Clinical trial, Food, Harvard Medical School, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disclosure, Review, Aspirin, Hypertension, Probability, SFJ, Research, Forward-looking statement, Headache, American Heart, Hypertensive emergency, Patient, Bleeding, FDA, Bentracimab, Private Securities Litigation Reform Act, Center, VIP, Union, PHAS, National Medical Products Administration, Twitter, U.S. Securities and Exchange Commission, Pharmacokinetics, European Union, BLA, Biologics license application, CA, Board, Partnership, Center for Drug Evaluation and Research, LinkedIn, Pivotal, Investigational New Drug, Bruise, Ticagrelor, Pamlab, IND, Pharmaceutical industry, Management

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today provided an update on corporate activities and reported third-quarter 2021 financial results.

Key Points: 
  • PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today provided an update on corporate activities and reported third-quarter 2021 financial results.
  • Details about the upcoming presentation were set forth in PhaseBios press release on October 6, 2021 .
  • PhaseBio is commencing preparation of the BLA and, subject to favorable results being observed, is targeting a BLA submission to the FDA in mid-2022.
  • Risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021.

Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

Retrieved on: 
Monday, October 25, 2021
Safety, Death, Cancer, Heart, Research, Myocarditis, Chest pain, CVD, Prognosis, Degenerative disease, University, Vaccine, McGill University Health Centre, University of Pittsburgh Medical Center, Mayo Clinic, History, Infection, Patient, Adoption, NASDAQ, FDA, Cardiovascular disease, Food, Cleveland, Health Canada, TSX, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Cleveland Clinic, Investigational New Drug, Company, Steroid, CRDL, COVID-19, Inflammation, Muscle tissue, Clinical professor, IND, Cannabidiol, Program, News, Therapy, Mortality, Hospital, Holy Spirit Hospital (Berlin), University of Ottawa Heart Institute, Houston Methodist Hospital, Desun Hospital & Heart Institute, Heart failure, Pharmaceutical industry

In addition, some patients proceed to develop chronic dilated cardiomyopathy which continues to be the leading indication for cardiac transplantation.

Key Points: 
  • In addition, some patients proceed to develop chronic dilated cardiomyopathy which continues to be the leading indication for cardiac transplantation.
  • Myocarditis has also been described as a complication of COVID-19 and, more recently, has been reported as a rare complication associated with certain vaccines for COVID-19.
  • Cardiol's acute myocarditis study is expected to enroll 100 patients at clinical centers in the United States, Canada, and Europe.
  • Given the risk of significant heart failure associated with acute myocarditis, current intervention includes drugs commonly administered for heart failure.

PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021

Retrieved on: 
Wednesday, October 6, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Surgery, Health, Clinical Trials, AHA, U.S. Securities and Exchange Commission, Disclosure, Food, Clinical trial, Mark (given name), Harvard Medical School, Ticagrelor, BLA, Partnership, Pharmacokinetics, Rapids, The New England Journal of Medicine, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Aspirin, FDA, Biologics license application, Bentracimab, American Heart Association, LinkedIn, Hypertension, Breakthrough therapy, PHAS, Twitter, CA, Company, Late, Hypertensive emergency, MPH, Bleeding, Research, VIP, Forward-looking statement, Desun Hospital & Heart Institute, Cardiology, Pharmaceutical industry

Presenting the results from this trial to a broad cross section of the cardiology community is an important milestone for PhaseBio and the REVERSE-IT trial.

Key Points: 
  • Presenting the results from this trial to a broad cross section of the cardiology community is an important milestone for PhaseBio and the REVERSE-IT trial.
  • Patients with reported use of ticagrelor within the prior 3 days who require urgent ticagrelor reversal are eligible for enrollment.
  • The Phase 1 clinical trial of bentracimab in healthy volunteers was published in the New England Journal of Medicine in March 2019.
  • Additionally, the Phase 2a trial investigated a bentracimab regimen for the reversal of supratherapeutic doses of ticagrelor in healthy younger subjects.

careMESH introduces TRANSITIONS service line to transform care team collaboration

Retrieved on: 
Thursday, September 9, 2021

Reston, Virginia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- careMESH , a healthcare communications platform that allows hospitals, physician practices, and other organizations to share patient information with any provider in the United States, today announced a new service line, careMESH TRANSITIONS.

Key Points: 
  • Reston, Virginia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- careMESH , a healthcare communications platform that allows hospitals, physician practices, and other organizations to share patient information with any provider in the United States, today announced a new service line, careMESH TRANSITIONS.
  • Using careMESH TRANSITIONS , clinical programs capture all referrals into a single, customizable dashboard.
  • Before careMESH, our team was utilizing spreadsheets and a cumbersome, manual process to enter all of the patient information.
  • TRANSITIONS builds on our core strengths of communicating with and sharing patient information with any provider nationwide, commented Dr. Peter S. Tippett , careMESH Founder and CEO.